{"id":6623,"date":"2026-02-09T15:40:17","date_gmt":"2026-02-09T15:40:17","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/6623\/"},"modified":"2026-02-09T15:40:17","modified_gmt":"2026-02-09T15:40:17","slug":"novo-nordisk-takes-legal-action-against-hims-hers-over-wegovy-knock-offs-hims-hers-health-nysehims-novo-nordisk-nysenvo","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/6623\/","title":{"rendered":"Novo Nordisk Takes Legal Action Against Hims &#038; Hers Over Wegovy Knock Offs &#8211; Hims &#038; Hers Health (NYSE:HIMS), Novo Nordisk (NYSE:NVO)"},"content":{"rendered":"<p class=\"block core-block\">Novo Nordisk A\/S <a href=\"https:\/\/www.benzinga.com\/quote\/NVO\" target=\"_blank\" class=\"ticker-link\" data-ticker=\"NVO\" data-exchange=\"NYSE\" rel=\"noopener nofollow\">(NYSE:<\/a><a class=\"ticker\" href=\"https:\/\/www.benzinga.com\/quote\/NVO\" target=\"_blank\" rel=\"nofollow noopener\">NVO<\/a>) on Monday said it has filed a lawsuit against telehealth company Hims &amp; Hers Inc. <a href=\"https:\/\/www.benzinga.com\/quote\/HIMS\" target=\"_blank\" class=\"ticker-link\" data-ticker=\"HIMS\" data-exchange=\"NYSE\" rel=\"noopener nofollow\">(NYSE:<\/a><a class=\"ticker\" href=\"https:\/\/www.benzinga.com\/quote\/HIMS\" target=\"_blank\" rel=\"nofollow noopener\">HIMS<\/a>) for infringing U.S. Patent 8,129,343 with Hims\u2019 <a target=\"_blank\" href=\"https:\/\/www.benzinga.com\/pressreleases\/26\/02\/g50474915\/novo-nordisk-takes-legal-action-against-hims-hers-to-protect-patients-from-unsafe-knock-off-wegovy\" rel=\"noreferrer noopener nofollow\">compounded semaglutide products<\/a> for the U.S. market.<\/p>\n<p>Novo Nordisk\u2019s Legal Move Explained<\/p>\n<p class=\"block core-block\">Novo Nordisk, in its press release, said Hims &amp; Hers engaged in promotional campaigns that highlight its compounded semaglutide products, duping consumers and healthcare professionals as to the clinical benefits and safety of these unapproved drugs.<\/p>\n<p class=\"block core-block\">Hims continues to unlawfully mass compound injectable versions, made with inauthentic API, and these knock-offs are putting patient health and well-being at risk, Novo claims.\u00a0\u00a0<\/p>\n<p class=\"block core-block\">Mass marketing by Hims and compounding pharmacies has flooded the market with knock-off Wegovy and Ozempic. Compounded semaglutide products may contain dangerous impurities or incorrect amounts of active ingredients, which can result in life-threatening immune responses, hospitalization, severe drug-drug interactions, and overdoses.<\/p>\n<p>Impurity Levels In Compounded Drugs<\/p>\n<p class=\"block core-block\">According to Novo Nordisk\u2019s testing, injectable semaglutide drugs compounded by pharmacies were found to contain impurities of up to 86%, with compounded oral semaglutide drugs containing impurities as high as 75%.<\/p>\n<p class=\"block core-block\">Even in small quantities, such impurities can negatively impact the safety and efficacy of a drug product, including unwanted immune responses like anaphylactic shock.<\/p>\n<p class=\"block core-block\">Price Action: NVO stock is up 6.84% at $50.90, and HIMS stock is down 26.93% at $16.83 at the last check on Monday, <a href=\"https:\/\/www.benzinga.com\/pro\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">according to Benzinga Pro.<\/a><\/p>\n<p class=\"block core-block\">Photo by Tobias Arhelger via Shutterstock<\/p>\n<p><a class=\"text-sm my-4\" href=\"https:\/\/www.benzinga.com\/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom\" rel=\"noreferrer nofollow noopener\" target=\"_blank\">Market News and Data brought to you by Benzinga APIs<\/a><\/p>\n<p class=\"copyright\">\u00a9 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.<\/p>\n<p class=\"block core-block\">To add Benzinga News as your preferred source on Google, <a href=\"https:\/\/google.com\/preferences\/source?q=https%3A%2F%2Fwww.benzinga.com\" rel=\"noreferrer nofollow noopener\" target=\"_blank\">click here<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk A\/S (NYSE:NVO) on Monday said it has filed a lawsuit against telehealth company Hims &amp; Hers&hellip;\n","protected":false},"author":2,"featured_media":6624,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[2085,2094,2089,2087,2090,2092,2088,5813,2093,2084,272,352,2095,2096,2099,2100],"class_list":{"0":"post-6623","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-category-biotech","9":"tag-category-general","10":"tag-category-health-care","11":"tag-category-large-cap","12":"tag-category-legal","13":"tag-category-movers","14":"tag-category-news","15":"tag-category-top-stories","16":"tag-category-trading-ideas","17":"tag-cms-wordpress","18":"tag-novo-nordisk","19":"tag-pageisbzpro-bz","20":"tag-symbol-hims","21":"tag-symbol-nvo","22":"tag-tag-weight-loss","23":"tag-tag-why-its-moving"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/6623","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=6623"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/6623\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/6624"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=6623"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=6623"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=6623"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}